Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese Patient

Abstract

Get full access to this article

View all access options for this article.

References

Xarelto (rivaroxaban) [product information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed November 16, 2014.

American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. Chest. 2012;141(2, suppl):e278S-e325S.

Gesell

Gonzalez Della Valle

Bartolome Garcia

. Safety and efficacy of multimodal thromboprophylaxis following total knee arthroplasty: a comparative study of preferential aspirin vs. routine chemoprophylaxis. J Arthroplasty. 2013;28:575-579.

Mueck

Borris

Dahl

. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.

Breuer

Ringwald

Schwab

Köhrmann

. Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med. 2013;368:2440-2442. doi:10.1056/NEJMc1215900.